Ziresovir sind in der Pipeline, monoklonale Antikörper wie Palivizumab und Nirsevimab stehen bereits zur Verfügung.
4/9
4/9
February 10, 2026 at 11:13 AM
Ziresovir sind in der Pipeline, monoklonale Antikörper wie Palivizumab und Nirsevimab stehen bereits zur Verfügung.
4/9
4/9
NPR really both sidesing one of the best medical breakthroughs of the past 5 years.
We have had RSV monoclonal antibodies for 2 decades (palivizumab). It was expensive, tricky to dose, and had to be given multiple times per season. The new ones are great.
We have had RSV monoclonal antibodies for 2 decades (palivizumab). It was expensive, tricky to dose, and had to be given multiple times per season. The new ones are great.
March 25, 2026 at 11:39 PM
NPR really both sidesing one of the best medical breakthroughs of the past 5 years.
We have had RSV monoclonal antibodies for 2 decades (palivizumab). It was expensive, tricky to dose, and had to be given multiple times per season. The new ones are great.
We have had RSV monoclonal antibodies for 2 decades (palivizumab). It was expensive, tricky to dose, and had to be given multiple times per season. The new ones are great.
I had plenty of criticism for Cody Meissner’s positions related to pediatric Covid vaccines, but he’s a Peds ID Doc with deep clinical trials experience (instrumental work on RSV prevention with palivizumab - synagis™️).
He called out the bullshit pretense of today’s ACIP meeting. I hope he resigns.
He called out the bullshit pretense of today’s ACIP meeting. I hope he resigns.
September 18, 2025 at 11:11 PM
I had plenty of criticism for Cody Meissner’s positions related to pediatric Covid vaccines, but he’s a Peds ID Doc with deep clinical trials experience (instrumental work on RSV prevention with palivizumab - synagis™️).
He called out the bullshit pretense of today’s ACIP meeting. I hope he resigns.
He called out the bullshit pretense of today’s ACIP meeting. I hope he resigns.
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first #RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season. #IDsky #Medsky
www.contagionlive.com/view/clesrov...
www.contagionlive.com/view/clesrov...
Clesrovimab Given in 1st and 2nd RSV Seasons for At-Risk Infants | Contagion Live
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in ...
www.contagionlive.com
October 3, 2026 at 12:01 PM
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first #RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season. #IDsky #Medsky
www.contagionlive.com/view/clesrov...
www.contagionlive.com/view/clesrov...
RSV infects 90% of children by age 2 and causes over 3 million hospitalizations annually. Palivizumab & nirsevimab are injectable monoclonal antibodies used for prevention in infants. #IDsky #MEDsky #PEDSsky
Read more from Contemp. Peds. May 2025 journal: www.contagionlive.com/view/rsv-pro...
Read more from Contemp. Peds. May 2025 journal: www.contagionlive.com/view/rsv-pro...
RSV Prophylaxis: Palivizumab, Nirsevimab, and More
Current prevention strategies include two injectables for infants and young children, namely palivizumab and nirsevimab.
www.contagionlive.com
May 9, 2025 at 1:30 PM
RSV infects 90% of children by age 2 and causes over 3 million hospitalizations annually. Palivizumab & nirsevimab are injectable monoclonal antibodies used for prevention in infants. #IDsky #MEDsky #PEDSsky
Read more from Contemp. Peds. May 2025 journal: www.contagionlive.com/view/rsv-pro...
Read more from Contemp. Peds. May 2025 journal: www.contagionlive.com/view/rsv-pro...
The previous generation monoclonal antibody, palivizumab, had strictly defined high risk indications such as prematurity and congenital heart disease. This was due to the high cost and short duration of protection.
We also had a functional ACIP at that time.
We also had a functional ACIP at that time.
January 11, 2026 at 5:14 PM
The previous generation monoclonal antibody, palivizumab, had strictly defined high risk indications such as prematurity and congenital heart disease. This was due to the high cost and short duration of protection.
We also had a functional ACIP at that time.
We also had a functional ACIP at that time.
RSV remains a severe infection in infants and children. In this report, data on the activity of clesrovimab, a long-lasting RSV monoclonal antibody, are described as compared with palivizumab. Full interim results for the SMART phase 3 trial: nej.md/4poVkDE
#MedSky #IDSky #PedSky
#MedSky #IDSky #PedSky
September 17, 2025 at 9:45 PM
RSV remains a severe infection in infants and children. In this report, data on the activity of clesrovimab, a long-lasting RSV monoclonal antibody, are described as compared with palivizumab. Full interim results for the SMART phase 3 trial: nej.md/4poVkDE
#MedSky #IDSky #PedSky
#MedSky #IDSky #PedSky
I concur. As a practicing pediatric pulmonologist for almost 30 years I am amazed how effective palivizumab and now nirsevimab have been in reducing the hospitalization rates due to RSV in babies. Nirsevimab is given to all babies and works. I’ve not seen sig side effects from either medication
December 10, 2025 at 3:59 AM
I concur. As a practicing pediatric pulmonologist for almost 30 years I am amazed how effective palivizumab and now nirsevimab have been in reducing the hospitalization rates due to RSV in babies. Nirsevimab is given to all babies and works. I’ve not seen sig side effects from either medication
There is another drug called Synagis that has been available longer than Beyfortus, but the requirements to qualify are more strict. www.synagis.com/index.html
SYNAGIS® (palivizumab)
Click to learn more information.
www.synagis.com
December 10, 2024 at 11:56 PM
There is another drug called Synagis that has been available longer than Beyfortus, but the requirements to qualify are more strict. www.synagis.com/index.html
Mas há mais na ignorância. Há anos que se utiliza o Palivizumab contra o vsr em grupos de risco. Porquê a troca? Porque o Palivizumab precisa de 5 doses durante a época epidemica, o novo precisa de 1 dose.
O nirsevimab é caro por dose, mas mais barato por criança.
O nirsevimab é caro por dose, mas mais barato por criança.
August 11, 2025 at 4:27 PM
Mas há mais na ignorância. Há anos que se utiliza o Palivizumab contra o vsr em grupos de risco. Porquê a troca? Porque o Palivizumab precisa de 5 doses durante a época epidemica, o novo precisa de 1 dose.
O nirsevimab é caro por dose, mas mais barato por criança.
O nirsevimab é caro por dose, mas mais barato por criança.
Today's ACIP meeting also featured a presentation from Merck regarding clesrovimab, an RSV monoclonal antibody targeting antigenic site IV (nirsevimab is site Ø and palivizumab is site II):
www.cdc.gov/acip/dow...
I'll summarize...
www.cdc.gov/acip/dow...
I'll summarize...
October 23, 2024 at 8:57 PM
Today's ACIP meeting also featured a presentation from Merck regarding clesrovimab, an RSV monoclonal antibody targeting antigenic site IV (nirsevimab is site Ø and palivizumab is site II):
www.cdc.gov/acip/dow...
I'll summarize...
www.cdc.gov/acip/dow...
I'll summarize...
Meissner is satisfied with the available data on the safety as is the RSV work group. Regarding concomitant administration with vaccines, there is no interference with vaccines on the schedule observed from administration of palivizumab, the previous generation passive immunoprophylaxis against...
June 26, 2025 at 12:43 PM
Meissner is satisfied with the available data on the safety as is the RSV work group. Regarding concomitant administration with vaccines, there is no interference with vaccines on the schedule observed from administration of palivizumab, the previous generation passive immunoprophylaxis against...
"But New Zealand was yet to introduce a universal infant RSV prevention programme. About 200 infants were deemed high-risk each year, those with serious heart or lung conditions or born very prematurely, and received the palivizumab vaccine."
July 22, 2026 at 5:09 PM
"But New Zealand was yet to introduce a universal infant RSV prevention programme. About 200 infants were deemed high-risk each year, those with serious heart or lung conditions or born very prematurely, and received the palivizumab vaccine."
8/ Treatment for RSV: 🌡️ Most cases are treated with supportive care:
Hydration 💧.
Nasal suction for congestion 🫁.
Oxygen therapy if severe. 💉
For high-risk infants, Palivizumab (antibody therapy) may prevent severe illness.
🚫 Antibiotics won’t work (it’s viral).
Hydration 💧.
Nasal suction for congestion 🫁.
Oxygen therapy if severe. 💉
For high-risk infants, Palivizumab (antibody therapy) may prevent severe illness.
🚫 Antibiotics won’t work (it’s viral).
November 23, 2024 at 3:42 PM
8/ Treatment for RSV: 🌡️ Most cases are treated with supportive care:
Hydration 💧.
Nasal suction for congestion 🫁.
Oxygen therapy if severe. 💉
For high-risk infants, Palivizumab (antibody therapy) may prevent severe illness.
🚫 Antibiotics won’t work (it’s viral).
Hydration 💧.
Nasal suction for congestion 🫁.
Oxygen therapy if severe. 💉
For high-risk infants, Palivizumab (antibody therapy) may prevent severe illness.
🚫 Antibiotics won’t work (it’s viral).
Nice paper looking at regional changes in RSV hospitalisation in Nova Scotia, Canada, when palivizumab eligibility stopped for 30-32 week babies. From 0 hospitalisation to 9% in this group.
Important to monitor epidemiology & potential associations
www.thieme-connect.com/products/ejo...
Important to monitor epidemiology & potential associations
www.thieme-connect.com/products/ejo...
Increased Respiratory Syncytial Virus-Associated Hospitalizations and Ambulatory Visits in Very Preterm Infants in the First Year of Life following Discontinuation of Access to Palivizumab
Thieme E-Books & E-Journals
www.thieme-connect.com
February 10, 2025 at 10:54 AM
Nice paper looking at regional changes in RSV hospitalisation in Nova Scotia, Canada, when palivizumab eligibility stopped for 30-32 week babies. From 0 hospitalisation to 9% in this group.
Important to monitor epidemiology & potential associations
www.thieme-connect.com/products/ejo...
Important to monitor epidemiology & potential associations
www.thieme-connect.com/products/ejo...
Manitoba updating RSV immunization program this fall, but not committing to universal coverage https://www.cbc.ca/news/canada/manitoba/rsv-immunization-update-1.7610653
𝗚𝗲𝘁 𝘄𝗲𝗲𝗸𝗹𝘆 𝘂𝗽𝗱𝗮𝘁𝗲𝘀 ⇢ CanadaHealthwatch.ca/newsletter
𝗚𝗲𝘁 𝘄𝗲𝗲𝗸𝗹𝘆 𝘂𝗽𝗱𝗮𝘁𝗲𝘀 ⇢ CanadaHealthwatch.ca/newsletter
August 19, 2025 at 2:55 AM
Manitoba updating RSV immunization program this fall, but not committing to universal coverage https://www.cbc.ca/news/canada/manitoba/rsv-immunization-update-1.7610653
𝗚𝗲𝘁 𝘄𝗲𝗲𝗸𝗹𝘆 𝘂𝗽𝗱𝗮𝘁𝗲𝘀 ⇢ CanadaHealthwatch.ca/newsletter
𝗚𝗲𝘁 𝘄𝗲𝗲𝗸𝗹𝘆 𝘂𝗽𝗱𝗮𝘁𝗲𝘀 ⇢ CanadaHealthwatch.ca/newsletter
Während gegen SARS-CoV-2 & Influenzaviren wirksame Impfstoffe relativ breit eingesetzt werden, waren die Möglichkeiten zur Prävention schwerer RSV-Infektionen bis dato beschränkt auf den seit über 20 Jahren verfügbaren monoklonalen Antikörper Palivizumab für Risikokinder unter 2 Jahren.
October 29, 2023 at 9:59 AM
Während gegen SARS-CoV-2 & Influenzaviren wirksame Impfstoffe relativ breit eingesetzt werden, waren die Möglichkeiten zur Prävention schwerer RSV-Infektionen bis dato beschränkt auf den seit über 20 Jahren verfügbaren monoklonalen Antikörper Palivizumab für Risikokinder unter 2 Jahren.
There were also differences in risk for persistent symptoms too:
RSV = hypoxemia, hospitalisation, & prematurity. Palivizumab was protective
SARS-CoV-2 = hospitalisation, & elevated inflammatory markers
Influenza = prolonged fever, acute-phase fatigue/myalgia, & hospitalisation
RSV = hypoxemia, hospitalisation, & prematurity. Palivizumab was protective
SARS-CoV-2 = hospitalisation, & elevated inflammatory markers
Influenza = prolonged fever, acute-phase fatigue/myalgia, & hospitalisation
September 22, 2026 at 11:21 PM
There were also differences in risk for persistent symptoms too:
RSV = hypoxemia, hospitalisation, & prematurity. Palivizumab was protective
SARS-CoV-2 = hospitalisation, & elevated inflammatory markers
Influenza = prolonged fever, acute-phase fatigue/myalgia, & hospitalisation
RSV = hypoxemia, hospitalisation, & prematurity. Palivizumab was protective
SARS-CoV-2 = hospitalisation, & elevated inflammatory markers
Influenza = prolonged fever, acute-phase fatigue/myalgia, & hospitalisation
#Medsky🧪 #IDsky #Microsky #pedsky #Drugdevelopment #drugdelivery #pharmsky #publichealth
Role of Neutralizing Antibodies in RSV & hMPV #VaccineDevelopment
In 2026, neutralizing antibodies (nAbs) are the primary immunological
Role of Neutralizing Antibodies in RSV & hMPV #VaccineDevelopment
In 2026, neutralizing antibodies (nAbs) are the primary immunological
January 19, 2026 at 5:56 AM
#Medsky🧪 #IDsky #Microsky #pedsky #Drugdevelopment #drugdelivery #pharmsky #publichealth
Role of Neutralizing Antibodies in RSV & hMPV #VaccineDevelopment
In 2026, neutralizing antibodies (nAbs) are the primary immunological
Role of Neutralizing Antibodies in RSV & hMPV #VaccineDevelopment
In 2026, neutralizing antibodies (nAbs) are the primary immunological
#Medsky🧪 #IDsky #pedsky #pharmsky #publichealth In this phase III study, a single 105-mg dose of #clesrovimab was well tolerated in infants at increased risk for severe RSV disease in their first RSV season, with a safety profile vs to #palivizumab.
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Clesrovimab in Infants at Increased Risk for Severe Disease During 2 RSV Seasons
This randomized clinical trial evaluates the safety and tolerability of single-dose clesrovimab across 2 respiratory syncytial virus (RSV) seasons in infants at high risk for severe RSV.
jamanetwork.com
July 21, 2026 at 4:47 AM
#Medsky🧪 #IDsky #pedsky #pharmsky #publichealth In this phase III study, a single 105-mg dose of #clesrovimab was well tolerated in infants at increased risk for severe RSV disease in their first RSV season, with a safety profile vs to #palivizumab.
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Ten eerste zijn er meedrere producten op de markt; Nirsevimab (AZ/Sanofi), Palivizumab (Synagis) en Clesrovimab (Merck). Het klopt dat dit monoclonale antilichamen zijn. Ideal, en dat zal in de toekomst misschien ook gebeuren, worden er meer dan 1 tegelijk gegeven.
2/8
2/8
September 9, 2025 at 12:54 PM
Ten eerste zijn er meedrere producten op de markt; Nirsevimab (AZ/Sanofi), Palivizumab (Synagis) en Clesrovimab (Merck). Het klopt dat dit monoclonale antilichamen zijn. Ideal, en dat zal in de toekomst misschien ook gebeuren, worden er meer dan 1 tegelijk gegeven.
2/8
2/8
#Medsky🧪 #IDSky #pedsky #pharmasky #immunosky #episky #publichealth #Palivizumab may be considered for the prevention of RSV infection in at-risk infants below 1 year of age :
1. Infants at risk for recurrent #pneumonia due to respiratory tract abnormalities or neuromuscular diseases.
1. Infants at risk for recurrent #pneumonia due to respiratory tract abnormalities or neuromuscular diseases.
June 12, 2025 at 1:07 PM
#Medsky🧪 #IDSky #pedsky #pharmasky #immunosky #episky #publichealth #Palivizumab may be considered for the prevention of RSV infection in at-risk infants below 1 year of age :
1. Infants at risk for recurrent #pneumonia due to respiratory tract abnormalities or neuromuscular diseases.
1. Infants at risk for recurrent #pneumonia due to respiratory tract abnormalities or neuromuscular diseases.
Sooooo
Synagis (palivizumab) has been around for 2 decades but it is significantly more expensive and has to be re-dosed every month. It is only given to the most at risk patients.
So the idea isn't exactly new but the ability to protect all babies is a potential game changer.
Synagis (palivizumab) has been around for 2 decades but it is significantly more expensive and has to be re-dosed every month. It is only given to the most at risk patients.
So the idea isn't exactly new but the ability to protect all babies is a potential game changer.
October 9, 2024 at 1:18 AM
Sooooo
Synagis (palivizumab) has been around for 2 decades but it is significantly more expensive and has to be re-dosed every month. It is only given to the most at risk patients.
So the idea isn't exactly new but the ability to protect all babies is a potential game changer.
Synagis (palivizumab) has been around for 2 decades but it is significantly more expensive and has to be re-dosed every month. It is only given to the most at risk patients.
So the idea isn't exactly new but the ability to protect all babies is a potential game changer.
If it's available and the parents consent buuuuuut...
Nirsevimab and Palivizumab are not immunizations in the classic sense in that they do not illicit an immune response. They are monoclonal antibodies.
Nirsevimab and Palivizumab are not immunizations in the classic sense in that they do not illicit an immune response. They are monoclonal antibodies.
November 15, 2023 at 10:11 PM
If it's available and the parents consent buuuuuut...
Nirsevimab and Palivizumab are not immunizations in the classic sense in that they do not illicit an immune response. They are monoclonal antibodies.
Nirsevimab and Palivizumab are not immunizations in the classic sense in that they do not illicit an immune response. They are monoclonal antibodies.
Clesrovimab has been modified with the YTE mutations to enhance its half-life to 44 days. Clesrovimab has been assessed in a Phase 2b/3 study compared with placebo (IMO it should have been compared with palivizumab).
October 23, 2024 at 8:57 PM
Clesrovimab has been modified with the YTE mutations to enhance its half-life to 44 days. Clesrovimab has been assessed in a Phase 2b/3 study compared with placebo (IMO it should have been compared with palivizumab).